HDAC inhibitors and their potential applications to glioblastoma therapy

OncoImmunology

Volumn 2, Issue 8, 2013, Pages

  Adamopoulou, Eleni ^a   Naumann, Ulrike ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Glioblastoma; HDAC inhibition; Immunomodulation; NK cells

Indexed keywords

BUTYRIC ACID; CELL PROTEIN; GAMMA INTERFERON; GELATINASE B; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; INTERLEUKIN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MATRIX METALLOPROTEINASE; NATURAL KILLER CELL RECEPTOR NKG2D; PROTEIN MICA; PROTEIN MICB; PROTEIN UL16; ROMIDEPSIN; TRICHOSTATIN A; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL DESTRUCTION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CELL CYCLE PROGRESSION; CYTOTOXIC LYMPHOCYTE; DOWN REGULATION; GAMMA DELTA T LYMPHOCYTE; GENE EXPRESSION REGULATION; GENE REPRESSION; GLIOBLASTOMA; HISTONE ACETYLATION; HUMAN; IMMUNOSURVEILLANCE; INNATE IMMUNITY; MUTATIONAL ANALYSIS; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHUMAN; PHARMACOLOGICAL BLOCKING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REGULATORY T LYMPHOCYTE; TUMOR ESCAPE; UPREGULATION;

EID: 84885785282     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.25219     Document Type: Article

References (10)

1. Eisele G, Wischhusen J, Mittelbronn M, Meyermann R, Waldhauer I, Steinle A, et al. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells. Brain 2006; 129:2416-25; PMID:16891318; http://dx.doi. org/10.1093/brain/awl205
2. Friese MA, Platten M, Lutz SZ, Naumann U, Aulwurm S, Bischof F, et al. MICA/NKG2D-mediated immunogene therapy of experimental gliomas. Cancer Res 2003; 63:8996-9006; PMID:14695218
3. Hagelkruys A, Sawicka A, Rennmayr M, Seiser C. The biology of HDAC in cancer: the nuclear and epigenetic components. Handb Exp Pharmacol 2011; 206:13-37; PMID:21879444; http://dx.doi.org/10.1007/978-3- 642-21631-2_2
4. Ropero S, Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol 2007; 1:19- 25; PMID:19383284; http://dx.doi.org/10.1016/j. molonc.2007.01.001
5. Armeanu S, Bitzer M, Lauer UM, Venturelli S, Pathil A, Krusch M, et al. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res 2005; 65:6321-9; PMID:16024634; http://dx.doi.org/10.1158/0008-5472.CAN-04-4252
6. Kim HJ, Bae SC. Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res 2011; 3:166-79; PMID:21416059
7. Yamanegi K, Yamane J, Kobayashi K, Ohyama H, Nakasho K, Yamada N, et al. Downregulation of matrix metalloproteinase-9 mRNA by valproic acid plays a role in inhibiting the shedding of MHC class I-related molecules A and B on the surface of human osteosarcoma cells. Oncol Rep 2012; 28:1585-90; PMID:22923031
8. Höring E, Podlech O, Silkenstedt B, Rota IA, Adamopoulou E, Naumann U. The histone deacetylase inhibitor trichostatin a promotes apoptosis and antitumor immunity in glioblastoma cells. Anticancer Res 2013; 33:1351-60; PMID:23564772
9. Galanis E, Jaeckle KA, Maurer MJ, Reid JM, Ames MM, Hardwick JS, et al. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol 2009; 27:2052-8; PMID:19307505; http://dx.doi. org/10.1200/JCO.2008.19.0694
10. Shen L, Ciesielski M, Ramakrishnan S, Miles KM, Ellis L, Sotomayor P, et al. Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models. PLoS One 2012; 7:e30815; PMID:22303460; http://dx.doi.org/10.1371/journal.pone.0030815